ClinicalTrials.gg
CompletedNCT03195491CheckMate870Updated Jul 18, 2024Results posted

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

A Phase 3 interventional study of Nivolumab in Lung Cancer and Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 120
400 · median 66
Started
2017
with 23 others
Phase 3
24 of 120
3 open now
Registered
48th of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 48th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.

03

Conditions studied

  • Lung Cancer
  • Non-Small Cell Lung Cancer

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

This study's enrollment of 400 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Advanced stage IIIB/IV NSCLC (Nonsquamous and squamous)
  • 1 to 2 prior systemic therapies
  • (ECOG) Performance Status of less than or equal to 1
  • Participants must have by computed tomography (CT) or magnetic resonance imaging (MRI)
  • Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to starting study treatment

Exclusion criteria

Exclusion Criteria:

  • Women with a positive pregnancy test at enrollment or prior to administration of study medication
  • Participants with active central nervous system
  • Participants with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of first dose of study drug
  • Participants with previous are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period
  • Participants with carcinomatous meningitis

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Monotherapy

    Nivolumab administered every two weeks

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Intravenous infusion administered over 30 minutes at 240 mg

    Also known as: Opdivo, BMS-936558

07

What researchers measure

Primary outcomes

  1. Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events

    Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post dose, up to approximately 36 months

Secondary outcomes

  1. Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events

    Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post dose, up to approximately 36 months

  2. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post dose, up to approximately 36 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).

    Time frame: From the first dose up to the date of death. Participants without documentation of death will be censored on the late date known to be alive, up to approximately 32 months

  4. Progression-Free Survival (PFS)

    PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From the first dose up to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause, up to approximately 30 months

  5. Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

    Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria

    Time frame: From first dose up to 100 days post last dose, up to approximately 36 months

  6. Number of Participants Experiencing Serious Adverse Events (SAEs)

    Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.

    Time frame: From first dose to 100 days post last dose, up to 36 months

  7. Objective Response Rate

    Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.

    Time frame: From the first dose date up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. Up to approximately 36 months

  8. Duration of Tumor Response

    Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.

    Time frame: From the date of first confirmed response to the date of the first documented tumor progression, up to approximately 30 months

  9. Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests

    Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria

    Time frame: From randomization to 100 days post last dose, up to 36 months

  10. Time to Treatment Failure (TTF)

    Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than "maximum clinical benefit" and "administrative reasons by sponsor". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).

    Time frame: From treatment assignment to disease progression, death or last dose date, up to approximately 16 months

08

Results

Posted Jul 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneNon-HBV ParticipantsHBV Participants
Started38317
Completed362
Not completed34715
Withdrew: Study drug toxicity253
Withdrew: Maximum clinical benefit50
Withdrew: Lost to follow-up10
Withdrew: Death30
Withdrew: Adverse event unrelated to study drug192
Withdrew: Disease progression2668
Withdrew: Other reasons100
Withdrew: Participant withdrew consent81
Withdrew: Participant no longer meets study criteria01
Withdrew: Participant request to discontinue study treatment100

Outcome measures

PrimaryNumber of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events

Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post dose, up to approximately 36 months
Reported as:
Count of participants · Participants
Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events
ParticipantsNon-HBV Participants
Gastrointestinal Adverse2
Hepatic Adverse Event8
Pulmonary Adverse Event5
Renal Adverse Event2
Skin Adverse Event7
SecondaryNumber of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events

Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post dose, up to approximately 36 months
Reported as:
Count of participants · Participants
Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events
ParticipantsHBV Participants
Gastrointestinal Adverse Event0
Hepatic Adverse Event0
Pulmonary Adverse Event0
Renal Adverse Event0
Skin Adverse Reaction1
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post dose, up to approximately 36 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsNon-HBV ParticipantsHBV Participants
Number of Participants Experiencing Adverse Events (AEs)37517
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).

Time frame:
From the first dose up to the date of death. Participants without documentation of death will be censored on the late date known to be alive, up to approximately 32 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsNon-HBV ParticipantsHBV ParticipantsAll Treated Participants
All treated participants14.16 (12.25 to 18.07)22.31 (10.02 to NA)14.65 (12.32 to 18.10)
PD-L1 < 1%——13.31 (10.87 to 17.71)
PD-L1 ≥ 1%——19.25 (12.94 to 23.46)
PD-L1 < 5%——14.65 (11.63 to 18.10)
PD-L1 ≥ 5%——18.37 (11.70 to 22.77)
PD-L1 < 10%——14.72 (12.35 to 18.76)
PD-L1 ≥ 10%——17.68 (10.78 to 21.03)
PD-L1 < 50%——16.23 (12.52 to 18.86)
PD-L1 ≥ 50%——14.75 (10.68 to 29.04)
PD-L1 Not Reportable——11.99 (9.17 to 19.19)
Squamous Tumor Histology——13.80 (10.78 to 18.37)
Non-squamous Tumor Histology——14.75 (11.70 to 19.32)
EGFR Mutation Positive——19.32 (11.24 to 31.74)
ALK translocation positive——16.48 (1.28 to NA)
SecondaryProgression-Free Survival (PFS)

PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From the first dose up to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause, up to approximately 30 months
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsNon-HBV ParticipantsHBV ParticipantsAll Treated Participants
All treated participants3.61 (2.33 to 3.75)2.04 (1.64 to 10.22)3.61 (2.33 to 3.75)
PD-L1 < 1%——2.33 (1.94 to 3.68)
PD-L1 ≥ 1%——4.73 (3.68 to 5.65)
PD-L1 < 5——2.37 (1.94 to 3.68)
PD-L1 ≥ 5——5.42 (3.68 to 5.65)
PD-L1 < 10——2.50 (1.94 to 3.68)
PD-L1 ≥ 10——5.45 (3.68 to 5.65)
PD-L1 < 50——3.58 (2.07 to 3.75)
PD-L1 ≥ 50——5.55 (2.23 to 7.33)
EGFR mutation positive——1.87 (1.71 to 4.73)
ALK translocation positive——1.91 (1.28 to 16.36)
Squamous subgroup——3.75 (3.06 to 5.55)
Non-squamous subgroup——2.79 (1.94 to 3.68)
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria

Time frame:
From first dose up to 100 days post last dose, up to approximately 36 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
ParticipantsNon-HBV ParticipantsHBV Participants
ALT OR AST > 3XULN161
ALT OR AST > 5XULN50
ALT OR AST > 10XULN40
ALT OR AST > 20XULN20
TOTAL BILIRUBIN > 2XULN40
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY00
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAY00
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.

Time frame:
From first dose to 100 days post last dose, up to 36 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsNon-HBV ParticipantsHBV Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)15712
SecondaryObjective Response Rate

Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.

Time frame:
From the first dose date up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. Up to approximately 36 months
Reported as:
Number · Percentage of participants
Objective Response Rate
Percentage of participantsNon-HBV ParticipantsHBV ParticipantsAll Treated Participants
All treated participants14.88 (11.47 to 18.85)17.65 (3.80 to 43.43)15.00 (11.65 to 18.88)
Squamous tumor histology——18.38 (12.26 to 25.93)
Non-squamous tumor histology——13.26 (9.41 to 17.95)
PD-L1 < 1%——6.32 (3.20 to 11.03)
PD-L1 ≥ 1%——25.60 (19.18 to 32.89)
PD-L1 < 5%——8.78 (5.29 to 13.52)
PD-L1 ≥ 5%——26.28 (19.13 to 34.48)
PD-L1 < 10%——10.81 (7.05 to 15.66)
PD-L1 ≥ 10%——25.00 (17.55 to 33.73)
PD-L1 < 50%——11.76 (8.19 to 16.20)
PD-L1 ≥ 50%——31.43 (20.85 to 43.63)
EGFR mutation positive——17.65 (6.76 to 34.53)
ALK translocation positive——10.00 (0.25 to 44.50)
SecondaryDuration of Tumor Response

Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.

Time frame:
From the date of first confirmed response to the date of the first documented tumor progression, up to approximately 30 months
Reported as:
Median · Months
Duration of Tumor Response
MonthsHBV ParticipantsNon-HBV ParticipantsAll Treated Participants
All treated participantsNA (8.15 to NA)19.38 (11.04 to 24.97)19.38 (11.04 to 24.97)
Squamous tumor histology——12.62 (8.11 to 25.33)
Non-squamous tumor histology——19.61 (9.49 to 27.60)
PD-L1 < 1%——19.38 (8.11 to 24.97)
PD-L1 ≥ 1%——16.11 (9.43 to 27.60)
PD-L1 < 5%——19.38 (8.11 to 24.97)
PD-L1 ≥ 5%——19.61 (9.33 to 29.70)
PD-L1 < 10%——12.06 (8.11 to 24.97)
PD-L1 ≥ 10%——21.13 (9.43 to NA)
PD-L1 < 50%——12.06 (8.15 to 24.97)
PD-L1 ≥ 50%——21.49 (9.30 to NA)
EGFR mutation positive——12.57 (5.59 to NA)
ALK translocation positive——19.42 (NA to NA)
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests

Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria

Time frame:
From randomization to 100 days post last dose, up to 36 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsNon-HBV ParticipantsHBV Participants
TSH > ULN871
TSH > ULN WITH TSH <= ULN AT BASELINE630
TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN361
TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN520
TSH > ULN WITH FT3/FT4 TEST MISSING741
TSH < LLN663
TSH < LLN WITH TSH >= LLN AT BASELINE563
TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN341
TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN322
TSH < LLN WITH FT3/FT4 TEST MISSING432
SecondaryTime to Treatment Failure (TTF)

Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than "maximum clinical benefit" and "administrative reasons by sponsor". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).

Time frame:
From treatment assignment to disease progression, death or last dose date, up to approximately 16 months
Reported as:
Median · Months
Time to Treatment Failure (TTF)
MonthsNon-HBV ParticipantsHBV ParticipantsAll Treated Participants
All treated participants2.23 (1.94 to 3.52)1.97 (1.41 to 10.22)2.10 (1.94 to 3.52)
Squamous Tumor Histology——3.68 (2.10 to 5.45)
Non-Squamous Tumor Histology——1.94 (1.87 to 2.50)
EGFR Mutation Positive——1.86 (1.68 to 3.65)
ALK Translocation Positive——1.91 (1.28 to 16.36)
PD-L1 < 1%——1.97 (1.87 to 2.92)
PD-L1 ≥ 1%——3.68 (2.17 to 5.55)
PD-L1 < 5%——1.97 (1.87 to 3.06)
PD-L1 ≥ 5%——3.68 (2.23 to 5.55)
PD-L1 < 10%——1.97 (1.87 to 3.09)
PD-L1 ≥ 10%——3.75 (2.23 to 5.55)
PD-L1 < 50%——2.14 (1.91 to 3.58)
PD-L1 ≥ 50%——4.11 (2.00 to 6.01)

Adverse events

Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 41 months). Serious Adverse events and other adverse events were assessed from date of first dose to 100 days following date of last dose (up to approximately 36 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-HBV Participants270/383 (70.5%)157/383 (41%)359/383 (93.7%)
HBV Participants9/17 (52.9%)12/17 (70.6%)17/17 (100%)
TOTAL279/400 (69.8%)169/400 (42.3%)376/400 (94%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventNon-HBV ParticipantsHBV ParticipantsTOTAL
PneumoniaInfections and infestations29/3834/1733/400
DyspnoeaRespiratory, thoracic and mediastinal disorders6/3832/178/400
DeathGeneral disorders2/3831/173/400
PyrexiaGeneral disorders2/3831/173/400
Diabetic ketoacidosisMetabolism and nutrition disorders1/3831/172/400
HyperglycaemiaMetabolism and nutrition disorders0/3831/171/400
HypokalaemiaMetabolism and nutrition disorders1/3831/172/400
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3831/174/400
Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3831/171/400
Spinal cord compressionNervous system disorders0/3831/171/400
Most frequent other events
Showing 10 of 117
Most frequent other events
EventNon-HBV ParticipantsHBV ParticipantsTOTAL
AnaemiaBlood and lymphatic system disorders155/3837/17162/400
CoughRespiratory, thoracic and mediastinal disorders85/3837/1792/400
PyrexiaGeneral disorders72/3836/1778/400
HyponatraemiaMetabolism and nutrition disorders52/3836/1758/400
Aspartate aminotransferase increasedInvestigations59/3835/1764/400
Decreased appetiteMetabolism and nutrition disorders94/3832/1796/400
LeukocytosisBlood and lymphatic system disorders21/3834/1725/400
Alanine aminotransferase increasedInvestigations62/3834/1766/400
Neutrophil count increasedInvestigations15/3834/1719/400
ConstipationGastrointestinal disorders39/3833/1742/400

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(Years)Non-HBV ParticipantsHBV ParticipantsTotal
Mean60.6 ± 8.7259.1 ± 7.8660.5 ± 8.68
Sex: Female, Male
Sex: Female, Male(Participants)Non-HBV ParticipantsHBV ParticipantsTotal
Female82486
Male30113314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Non-HBV ParticipantsHBV ParticipantsTotal
Chinese37717394
Asian Other606
09

Study locations

30 sites
  • Local Institution
    Beijing, Beijing 100001, China
  • Local Institution
    Beijing, Beijing 100142, China
  • Local Institution
    Beijing, Beijing 100730, China
  • Local Institution
    Beijing, Beijing 101149, China
  • Local Institution
    Fuzhou, Fujian 350014, China
  • Local Institution
    Guangzhou, Guangdong 510080, China
  • Local Institution
    Beijing, Hebei 100031, China
  • Local Institution
    Harbin, Heilongjiang 150081, China
  • Local Institution
    Zhengzhou, Henan 450008, China
  • Local Institution
    Wuhan, Hubei 430022, China
  • Local Institution - 0017
    Changsha, Hunan 410013, China
  • Local Institution
    Nanjing, Jiangsu 210002, China
  • Local Institution
    Nanjing, Jiangsu 210008, China
  • Local Institution
    Changchun, Jilin 130012, China
  • Local Institution
    Changchun, Jilin 130021, China
  • Local Institution
    Xi'an, Shan3xi 710038, China
  • Local Institution
    Jinan, Shandong 250031, China
  • Local Institution
    Shanghai, Shanghai 200025, China
  • Local Institution
    Shanghai, Shanghai 200032, China
  • Local Institution
    Tianjin, Tianjin 300222, China
  • Local Institution
    Urumqi, Xinjiang 830011, China
  • Local Institution
    Hangzhou, Zhejiang 310000, China
  • Local Institution
    Hangzhou, Zhejiang 310003, China
  • Local Institution
    Hangzhou, Zhejiang 310022, China
  • Local Institution
    Guangzhou, China
  • Local Institution
    Shanghai, 200030, China
  • Local Institution
    Shanghai, 200032, China
  • Local Institution
    Shenyang, 110042, China
  • Local Institution
    Bangkok, 10700, Thailand
  • Local Institution
    Khon Kaen, 40002, Thailand
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2021, 41 months.

Results were first posted in Jul 2024, 3 years 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 41 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 22, 2017
StartActual
Dec 25, 2017
Primary completionActual
Jun 8, 2021
CompletionActual
Jun 8, 2021
Results first posted
Jul 18, 2024
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03195491
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Dec 25, 2017
Primary completion
Jun 8, 2021
Completion
Jun 8, 2021
Results posted
Jul 18, 2024
Last update
Jul 18, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion